Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Accumulated Expenses (2017 - 2025)

Autolus Therapeutics' Accumulated Expenses history spans 9 years, with the latest figure at $55.8 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 6.73% year-over-year to $55.8 million; the TTM value through Dec 2025 reached $55.8 million, up 6.73%, while the annual FY2025 figure was $55.8 million, 6.73% up from the prior year.
  • Accumulated Expenses reached $55.8 million in Q4 2025 per AUTL's latest filing, up from $52.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $55.8 million in Q4 2025 to a low of $23.7 million in Q4 2021.
  • Average Accumulated Expenses over 5 years is $39.6 million, with a median of $37.8 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: fell 14.81% in 2021, then soared 72.38% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $23.7 million in 2021, then skyrocketed by 72.38% to $40.8 million in 2022, then dropped by 2.98% to $39.6 million in 2023, then skyrocketed by 32.07% to $52.3 million in 2024, then grew by 6.73% to $55.8 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Accumulated Expenses are $55.8 million (Q4 2025), $52.3 million (Q3 2025), and $51.4 million (Q2 2025).